Skip to main content
Have a personal or library account? Click to login
Long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a 15-year national referral centre experience Cover

Long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a 15-year national referral centre experience

By:  and    
Open Access
|Oct 2026
Read online

Figures & Tables

TABLE 1.

Clinical data of patient and tumour characteristics

N (%)
Sex
  Male9 (24.3)
  Female28 (75.7)
Mean age, years (range)55 (30–78)
Histopathological diagnosis
  LAMN32 (86.5)
  HAMN2 (5.4)
  Ovarian mucinous borderline tumour3 (8.1)
Peritoneal Cancer Index (PCI)17.19
  Mean (range)(1–39)
Completeness of Cytoreduction (CC) Score
  0/134 (91.9)
  23 (8.1)
  30
Prior Surgical Score (PSS)
  010 (27)
  114 (37.8)
  28 (21.6)
  35 (13.5)
Median Lenght of Hospital Stay days (range)18 (8–112)
Complications Clavien-Dindo III/IV7 (18.9)

[i] HAMN = high grade appendiceal mucinous neoplasm; LAMN = low grade appendiceal mucinous neoplasm

FIGURE 1.

Kaplan- Meier curve: overall survival (OS) in presented patient cohort

TABLE 2.

Univariate analysis, factors affecting overall survival (OS)

P
SexNS
AgeNS
Prior Surgical Score (PSS)NS
Peritoneal Cancer Index (PCI)0.003
  Completeness of Cytoreduction Score (CC)0.025
ASANS
HistologyNS
CEA0.004
CA 19-90.008
CA 125NS

[i] ASA = American Society of Anesthesiologists Physical Status Classification; CA 125 = Cancer Antigen 125; CA 19-9 = Carbohydrate Antigen 19-9; CEA = Carcinoembryonic Antigen; NS = not significant

FIGURE 2.

Kaplan-Meier curves: overall survival (OS) according to Peritoneal Cancer Index (PCI) score category

TABLE 3.

Multivariate analysis, independent prognostic factors of overall survival (OS)

P
SexNS
AgeNS
Prior Surgical Score (PSS)NS
Peritoneal Cancer Index (PCI)NS
Completeness of Cytoreduction Score (CC)0.013
ASANS
HistologyNS
CEANS
CA 19-90.025
CA 125NS

[i] ASA = American Society of Anesthesiologists Physical Status Classification; CA 125 = Cancer Antigen 125; CA 19-9 = Carbohydrate Antigen 19-9; CEA = Carcinoembryonic Antigen; NS = not significant

TABLE 4.

Univariate analysis of factors affecting disease free survival (DFS)

P
Sex0.005
Age0.036
Prior Surgical Score (PSS)NS
Peritoneal Cancer Index (PCI)0.004
Completeness of Cytoreduction Score (CC)0.007
ASANS
HistologyNS
CEANS
CA 19-9NS
CA 125NS

[i] ASA = American Society of Anesthesiologists Physical Status Classification; CA 125 = Cancer Antigen 125; CA 19-9 = Carbohydrate Antigen 19-9; CEA = Carcinoembryonic Antigen; NS = not significant

TABLE 5.

Multivariate analysis, disease-free survival (DFS)

P
SexNS
AgeNS
Prior Surgical Score (PSS)NS
Peritoneal Cancer Index (PCI)NS
Completeness of Cytoreduction Score (CC)0.014
ASANS
HistologyNS
CEANS
CA 19-9NS
CA 125NS

[i] ASA = American Society of Anesthesiologists Physical Status Classification; CA 125 = Cancer Antigen 125; CA 19-9 = Carbohydrate Antigen 19-9; CEA = Carcinoembryonic Antigen; NS = not significant

TABLE 6.

Comparison of the present study with representative published series

StudyNCC0/1Major morbidity (Clavien-Dindo III–V)Mortality (%)5-year OS
Youssef334566671.669
Elias1030173404.473
Deraco117596178
Narasimhan131407320.6071
Santullo12509410091
Present study3791.918.9091.9
DOI: https://doi.org/10.2478/raon-2026-0054 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Submitted on: Jul 2, 2026
Accepted on: Aug 28, 2026
Published on: Oct 22, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Rok Petric, Gasper Pilko, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.